Suppr超能文献

在中低收入国家采用新的卫生产品:产品开发伙伴关系如何支持国家决策。

Adoption of new health products in low and middle income settings: how product development partnerships can support country decision making.

机构信息

Global Alliance for TB Drug Development, 40 Wall St, New York NY 10005 USA.

出版信息

Health Res Policy Syst. 2011 Mar 31;9:15. doi: 10.1186/1478-4505-9-15.

Abstract

When a new health product becomes available, countries have a choice to adopt the product into their national health systems or to pursue an alternate strategy to address the public health problem. Here, we describe the role for product development partnerships (PDPs) in supporting this decision-making process. PDPs are focused on developing new products to respond to health problems prevalent in low and middle income settings. The impact of these products within public sector health systems can only be realized after a country policy process. PDPs may be the organizations most familiar with the evidence which assists decision making, and this generally translates into involvement in international policy development, but PDPs have limited reach into endemic countries. In a few individual countries, there may be more extensive involvement in tracking adoption activities and generating local evidence. This local PDP involvement begins with geographical prioritization based on disease burden, relationships established during clinical trials, PDP in-country resources, and other factors. Strategies adopted by PDPs to establish a presence in endemic countries vary from the opening of country offices to engagement of part-time consultants or with long-term or ad hoc committees. Once a PDP commits to support country decision making, the approaches vary, but include country consultations, regional meetings, formation of regional, product-specific committees, support of in-country advocates, development of decision-making frameworks, provision of technical assistance to aid therapeutic or diagnostic guideline revision, and conduct of stakeholder and Phase 4 studies. To reach large numbers of countries, the formation of partnerships, particularly with WHO, are essential. At this early stage, impact data are limited. But available evidence suggests PDPs can and do play an important catalytic role in their support of country decision making in a number of target countries.

摘要

当一种新的健康产品问世时,各国可以选择将该产品纳入国家卫生系统,也可以选择采取其他策略来解决公共卫生问题。在这里,我们描述了产品开发伙伴关系(PDP)在支持这一决策过程中的作用。PDP 专注于开发新产品,以应对中低收入国家普遍存在的健康问题。这些产品在公共部门卫生系统中的影响只有在国家政策过程之后才能实现。PDP 可能是最熟悉有助于决策的证据的组织,这通常转化为参与国际政策制定,但 PDP 对流行国家的影响力有限。在少数个别国家,可能会更广泛地参与跟踪采用活动和生成本地证据。这种本地 PDP 参与始于根据疾病负担进行地理优先排序、临床试验期间建立的关系、PDP 在国内的资源以及其他因素。PDP 为在流行国家建立存在而采用的策略从开设国家办事处到聘请兼职顾问或建立长期或临时委员会不等。一旦 PDP 承诺支持国家决策,方法就会有所不同,但包括国家协商、区域会议、组建区域、特定产品委员会、支持国内倡导者、制定决策框架、提供技术援助以帮助修订治疗或诊断指南,以及进行利益相关者和第 4 阶段研究。为了覆盖更多的国家,建立伙伴关系,特别是与世界卫生组织(WHO)的伙伴关系是必不可少的。在这个早期阶段,影响数据有限。但现有证据表明,PDP 可以并且确实在支持一些目标国家的国家决策方面发挥了重要的催化作用。

相似文献

4
The future of Cochrane Neonatal.考克兰新生儿协作网的未来。
Early Hum Dev. 2020 Nov;150:105191. doi: 10.1016/j.earlhumdev.2020.105191. Epub 2020 Sep 12.
10
New vaccine adoption in lower-middle-income countries.中低收入国家的新型疫苗接种。
Health Policy Plan. 2012 May;27 Suppl 2:ii39-49. doi: 10.1093/heapol/czs036.

本文引用的文献

2
A policy framework for accelerating adoption of new vaccines.加速新型疫苗采用的政策框架。
Hum Vaccin. 2010 Dec;6(12):1021-4. doi: 10.4161/hv.6.12.13076. Epub 2010 Dec 1.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验